Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.

Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:

Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism

Showing studies that mention “prostate cancer”.

Human onlyPositive outcomesSafety signalsTrials2 of 72 studies

ReviewMechanismMixed resultsLimited evidenceTier 1 · lab

Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule?

International journal of molecular sciences · Aug 2021 · review

breast cancercolon cancerprostate cancerendometrial cancerthyroid cancerbladder cancerglioblastomaadrenocortical carcinomaovarian epithelial carcinoma

This review discusses nucleobindin-2/nesfatin-1 (NUCB2/NESF-1) as a cancer-related molecule. It summarizes reports that higher expression is linked with poorer outcomes and with increased cancer cell proliferation, migration, and invasion in several cancers, while other reports suggest it may inhibit growth in some cancer cell types. The article does not present new experimental data.

Key findings

High NUCB2/NESF-1 expression has been associated with poor outcomes in several cancers.
Reported effects include increased cell proliferation, migration, and invasion in breast, colon, prostate, endometrial, thyroid, and bladder cancers, and glioblastoma.
The review also notes conflicting findings where nesfatin-1 inhibited proliferation in human adrenocortical carcinoma and ovarian epithelial carcinoma cells.
The authors propose NUCB2/NESF-1 as a prognostic and predictive marker in cancers.

Limitations: Review article; no original experimental or clinical data.; The abstract summarizes heterogeneous prior studies with conflicting findings.; No quantitative effect estimates are reported in the abstract.; No details on study quality, sample sizes, or methods of the cited studies are provided..

This is a review of a molecule reported to be associated with cancer progression and prognosis, not a primary intervention study.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewTrialReported positiveModerate evidenceTier 4 · clinical

Fuzuloparib: First Approval

Drugs · Jul 2021 · review article summarizing drug development and approval

Fuzuloparibovarian cancerfallopian tube cancerprimary peritoneal cancersolid cancerspancreatic cancerbreast cancerprostate cancerlung cancer

This review describes fuzuloparib, an oral PARP inhibitor, and its development leading to approval in China. The approval was for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with a germline BRCA mutation after second-line or later chemotherapy. The abstract also notes that phase II and III trials are ongoing in other solid cancers.

Key findings

Fuzuloparib is an orally active PARP inhibitor.
It has been approved in China for platinum-sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in patients with germline BRCA mutation after second-line or above chemotherapy.
Phase II and III trials are investigating it in other solid cancers.

Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..

This is a drug approval review focused on fuzuloparib's use in ovarian and related cancers, not an experimental efficacy study.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text